NCT02154646View on ClinicalTrials.gov

A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

July 31, 2015

Conditions
Pancreatic Neoplasms
Interventions
DRUG

LY2157299

Administered orally

DRUG

Gemcitabine

Administered IV

Trial Locations (2)

277 8577

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba

104-0045

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02154646 - A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body | Biotech Hunter | Biotech Hunter